03.14.14
With the trend toward avoiding the knife and treating skin on a cellular level, Histogen Aesthetics, a subsidiary of regenerative medicine company Histogen, Inc., focused on skin care and cosmeceuticals, has acquired the CellCeuticals Biomedical Skin Treatments line of skin care products.
Histogen Aesthetics will continue sales of the 11 existing CellCeuticals Biomedical Skin Treatments skin care products, while bringing new innovation to the line through the addition of what it calls “a unique regenerative medicine technology, working to improve skin aging at a cellular level.”
“We have long admired the science, clinical data and elegant formulas behind the CellCeuticals line, and see it as an ideal fit for our recently revitalized aesthetics subsidiary,” said Dr. Gail K. Naughton, CEO and chairman of Histogen, Inc. “We are very excited to begin infusing unique cell-signaling factors into the CellCeuticals regimen, to truly transform skin one cell at a time.”
Dr. Naughton has spent more than 30 years in tissue engineering and regenerative medicine, and holds over 100 patents in the field. She founded Histogen in 2007, focused on developing therapies that work to stimulate the stem cells in the body to regenerate tissues and organs. Through this work, she has also seen how different compositions of human proteins can have cosmetic benefits, particularly in anti-aging and rejuvenation.
“I am pleased that the CellCeuticals Biomedical Skin Treatments will evolve, and see Histogen Aesthetics as an excellent home for this innovative product line,” said Paul Scott Premo, co-founder of CellCeuticals Skin Care, Inc. “I believe the addition of this regenerative medicine technology will be the opportunity to introduce a new generation of products that are the vanguard of regenerative skin care.”
The CellCeuticals system is comprised of 11 distinctive products including the Extremely Gentle Skin Cleanser, CellGenesis Regenerative Skin Treatment, and PhotoDefense Color Radiance SPF55+ with proprietary and patented PhotoPlex technology.
Histogen Aesthetics will continue sales of the 11 existing CellCeuticals Biomedical Skin Treatments skin care products, while bringing new innovation to the line through the addition of what it calls “a unique regenerative medicine technology, working to improve skin aging at a cellular level.”
“We have long admired the science, clinical data and elegant formulas behind the CellCeuticals line, and see it as an ideal fit for our recently revitalized aesthetics subsidiary,” said Dr. Gail K. Naughton, CEO and chairman of Histogen, Inc. “We are very excited to begin infusing unique cell-signaling factors into the CellCeuticals regimen, to truly transform skin one cell at a time.”
Dr. Naughton has spent more than 30 years in tissue engineering and regenerative medicine, and holds over 100 patents in the field. She founded Histogen in 2007, focused on developing therapies that work to stimulate the stem cells in the body to regenerate tissues and organs. Through this work, she has also seen how different compositions of human proteins can have cosmetic benefits, particularly in anti-aging and rejuvenation.
“I am pleased that the CellCeuticals Biomedical Skin Treatments will evolve, and see Histogen Aesthetics as an excellent home for this innovative product line,” said Paul Scott Premo, co-founder of CellCeuticals Skin Care, Inc. “I believe the addition of this regenerative medicine technology will be the opportunity to introduce a new generation of products that are the vanguard of regenerative skin care.”
The CellCeuticals system is comprised of 11 distinctive products including the Extremely Gentle Skin Cleanser, CellGenesis Regenerative Skin Treatment, and PhotoDefense Color Radiance SPF55+ with proprietary and patented PhotoPlex technology.
